Skip to main content
. 2022 Jul 22;41(1):107–116. doi: 10.1200/JCO.22.00430

FIG 5.

FIG 5.

PFS according to KELIM (favorable or unfavorable) and treatment arms ([A] VEL-concurrent arm 2 v placebo [control] arm 1 and [B] VEL-throughout arm 3 v placebo [control] arm 1) in patients operated with PDS carrying tumors associated with HRP. HRP, homologous recombination proficiency; KELIM, elimination rate constant K; NA, not available; PDS, primary debulking surgery; PFS, progression-free survival; VEL, veliparib.